Full Breakdown
GSK Acquires 35Pharma to Enhance Pulmonary Hypertension Treatment Pipeline
2/25/2026, 8:35:55 PM
Acquisition Overview
GSK plc has announced a strategic agreement to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for $950 million in cash. This acquisition focuses on HS235, an investigational activin signaling inhibitor aimed at treating pulmonary hypertension (PH), a life-threatening condition affecting approximately 82 million people globally. The deal is subject to regulatory approvals under the Hart-Scott-Rodino Act in the U.S. and the Competition Act in Canada.
HS235: A Promising Therapeutic Candidate
HS235 has completed Phase I clinical trials in healthy volunteers and is poised to enter studies targeting two specific forms of PH: pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). The global market for PH therapies is projected to reach $18 billion by 2032, with activin signaling inhibitors expected to account for 50% of this market.
HS235 is designed to minimize adverse effects associated with existing treatments, particularly the risk of bleeding, which is crucial as many patients require anticoagulant or antiplatelet therapy. Additionally, HS235 may offer metabolic benefits, including fat-selective weight loss, preservation of lean mass, and improved insulin sensitivity, addressing multiple health dimensions relevant to the PH population.
Strategic Implications for GSK
This acquisition marks GSK's second major deal under the leadership of new CEO Luke Miels, who aims to accelerate the company's development pipeline amid looming patent expirations for key products. Miels has emphasized "smart business development" as a critical strategy for enhancing GSK's portfolio, which also includes a recent $2.2 billion acquisition of Rapt Therapeutics.
Tony Wood, GSK's Chief Scientific Officer, expressed optimism about HS235's potential, stating, “Pulmonary hypertension affects millions of people worldwide, yet patients are underserved.” He highlighted HS235's unique profile, which could provide broader coverage across various chronic diseases affecting the lung, liver, and kidney.
Market Context and Competitive Landscape
The competitive landscape for PH treatments includes Merck & Co.'s Winrevair, which generated $1.4 billion in sales last year. GSK aims to position HS235 as a superior alternative by demonstrating its ability to lower bleeding risks while delivering additional metabolic benefits. The success of HS235 in clinical trials could significantly impact GSK's standing in the rapidly growing PH market.
Official Statements & Responses
GSK's announcement reflects a commitment to addressing unmet medical needs in PH, with Miels stating, “To accelerate the pipeline we need to have more scientific courage and be more agile to capitalize on opportunities when we see them.” Ilia Tikhomirov, CEO of 35Pharma, noted the alignment of visions between the two companies, emphasizing the potential of HS235 to transform treatment for this debilitating condition.
What's Next
The acquisition is pending regulatory approvals, and GSK is expected to move quickly to initiate further clinical trials for HS235. Investors and stakeholders will be closely monitoring the progress of HS235 and other pipeline developments as GSK aims to enhance its market position and address the needs of PH patients.
